Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/106523
Título: | Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death | Autor: | Silva, Lígia C. Gomes da Kepp, Oliver Kroemer, Guido |
Palavras-chave: | Cetuximab saratolacan; photosensitizer IR700; EGFR; immunogenic cell death; head and neck cancer | Data: | 27-Out-2020 | Editora: | Taylor & Francis | Título da revista, periódico, livro ou evento: | OncoImmunology | Volume: | 9 | Número: | 1 | Resumo: | In September 2020, the Japanese government approved cetuximab saratolacan (previously known as RM-1929, commercial name: Akalux) for the treatment of unresectable locally advanced or recurrent head and neck cancer. Cetuximab saratolacan is a chemical conjugate of the photosensitizer IR700 with cetuximab, which targets EGFR. The treatment consists in the intravenous injection of cetuximab saratolacan, which binds to head and neck cancer cells expressing high levels of EGFR, followed by illumination of the tumor with red light (690 nm) for photodynamic therapy. This approach causes immunogenic cell death in malignant tissues, thus triggering a potent anticancer immune response. | URI: | https://hdl.handle.net/10316/106523 | ISSN: | 2162-4011 | DOI: | 10.1080/2162402X.2020.1841393 | Direitos: | openAccess |
Aparece nas coleções: | I&D CQC - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Regulatory-approval-of-photoimmunotherapy-photodynamic-therapy-that-induces-immunogenic-cell-deathOncoImmunology.pdf | 1.05 MB | Adobe PDF | Ver/Abrir |
Visualizações de página
51
Visto em 17/jul/2024
Downloads
31
Visto em 17/jul/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons